Glycemic Profiles of Healthy Individuals with Low Fasting Plasma Glucose and HbA1c by Nomura, Kyoko et al.
International Scholarly Research Network
ISRN Endocrinology




Low Fasting Plasma Glucose and HbA1c
Kyoko Nomura,1 Tomoyuki Saitoh,2 GwangU. Kim,3 andToshikazu Yamanouchi4
1Department of Hygiene and Public Health, School of Medicine, Teikyo University, Kaga 2-11-1, Itabashi, Tokyo 173-8605, Japan
2Faculty of Pharmaceutical Sciences, Teikyo University, Kaga 2-11-1, Itabashi, Tokyo 173-8605, Japan
3Division of Internal Medicine, Nishi-Arai Hospital, Nishiarai honcho 5-7-14, Adachi, Tokyo 123-0845, Japan
4Department of Internal Medicine, Teikyo University Hospital, Kaga 2-11-1, Itabashi, Tokyo 173-8605, Japan
Correspondence should be addressed to Kyoko Nomura, dzb07241@nifty.ne.jp
Received 11 October 2011; Accepted 30 October 2011
Academic Editors: W. B. Chan and A. Petryk
Copyright © 2011 Kyoko Nomura et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Scant data exists on glucose proﬁle variability in healthy individuals. Twenty-nine healthy subjects without diabetes (86% male;
mean age, 38 years) were measured by a CGM system and under real-life conditions. The median percentage of time spent on
the blood glucose >7.8mmol/L for 24hrs was greater than 10% in both NFG and IFG groups. When subjects were divided into
either NFG group (i.e., FPG levels of <5.6mmol/L; n=22) or IFG group (FPG levels of 5.6–6.9mmol/L; n=7), all CGM indicators
investigated but GRADE scores, including glucose variability measures, monitoring excursions, hyperglycemia, hypoglycemia, and
24-hour AUC, did not diﬀer signiﬁcantly between the two groups. GRADE score and its euglycemia% were signiﬁcantly diﬀerent
between the two groups. Among various CGM indicators, GRADE score may be a sensitive indicator to discriminate glucose
proﬁles between subjects with NFG and those with IFG.
1.Introduction
Literatures suggest that the extent of glucose levels may
be related to the subsequent development of diabetes even
among healthy individuals. For example, two large-scale
epidemiological studies have demonstrated a clear diabetes
risk gradient in glycemic levels within what was previously
considered the “normal” proﬁle (i.e., an fasting plasma
glucose (FPG) level of 100mg/dL and a Hemoglobin A1c
(HbA1c)levelof6.0%[1,2]).Inadditiontotheevidencethat
the strong independent association is observed between the
level of normal fasting plasma glucose (NFG) and the inci-
dence of diabetes, another study demonstrated the powerful
eﬀects of impaired fasting glucose (IFG) or impaired glucose
tolerance (IGT) on the development of diabetes [3]. These
literatures suggest that glucose proﬁles in healthy individuals
may be diﬀerent depending on glycemic categories such as
normal fasting glucose, IFG, and IGT.
In this study, we investigated diﬀerences in glycemic
proﬁles between healthy subjects with NFG and those with
IFG by utilizing a continuous glucose monitoring (CGM)
system. The CGM system (Medtronic Minimed, Northridge,
Calif), a valid and reliable, minimally invasive system,
enables the analysis of various glucose patterns that are
not assessable by conventional glucose indicators [4]. A
recent CGM study demonstrated that in a group of healthy
individuals without diabetes selected on the basis of a very
low baseline FPG level, 10% of subjects registered glucose
levels that were considered to be “prediabetic” or indicative
of a considerable period of IGT [5]. Given than few data




2.1. Subjects and Materials. Thirty-seven healthy adult Japa-
nese subjects, who were medical doctors and pharmaceutical
sales representatives, were recruited to this study. The
study subjects were further selected on the basis of (1)2 ISRN Endocrinology
having no history of diabetes, hypertension, and metabolic
syndrome and (2) a plasma glucose level of <7mmol/l after
an overnight fast, HbA1c level of <6.0%, or plasma 1,5-
anhydroglucitol (1,5-AG) level of >14.0µg/mL. Accordingly,
29 subjects were enrolled in this study after they provided
written informed consent. The study protocol was approved
by the institutional review board of Nishi-Arai Hospital.
2.2. Clinical Evaluation and Laboratory Measurements. Plas-
ma glucose level was measured using the hexokinase-G6PD
method (Denka Seiken, Niigata, Japan). Plasma 1,5-AG level
was determined with an autoanalyser system (Automatic
Clinical Analyzer, Model 7150 Hitachi Tokyo, Japan) using a
modiﬁed column enzymatic test. Serum insulin values were
measured using a chemiluminescent enzyme immunoassay.
Homeostasis of minimal assessment of insulin resistance
(HOMA-IR) was calculated from the FPG level and the
immunoreactive insulin (IRI) level using the formula:
HOMA-IR = [FPG (mmol/l) ×IRI (µU/mL)]/22.5.
A borderline level of insulin resistance was deﬁned as a
HOMA-IR score of ≥1.6, and deﬁnite insulin resistance as a
HOMA-IR score of ≥2.5. Pancreatic beta-cell function (i.e.,
HOMA-B) was quantiﬁed using the equation: HOMA-B =
IRI (µU/mL) ×20/[FPG (mmol/mL) −3.5].
HbA1c level was measured by immunoassay using
monoclonal antibodies (DM-JACK; Kyowa Medex, Tokyo,
Japan). Because the measurement range for HbA1c was in
accordance with the guidelines of the Japan Diabetes Society,
results were converted into National Glycohemoglobin Stan-
dardization Program (NGSP) values by adding 0.4% based
on the equation: NGSP value (%) = JDS value (%) +0.4%.
2.3. CGM System Measurement and Indicators. MiniMed
CGM system sensors were inserted into subjects for 48hrs.
Finger stick glucose levels were measured every 8hrs for
calibration.DuringCGM,noattemptwasmadetostandard-
ize participant behavior, for example, by controlling dietary
calorie intake or exercise. Instead, subjects were asked to
modify their usual daily behavior as little as possible.
The CGM measures investigated were mean blood
glucose (MBG), standard deviation (SD), largest amplitude
of glycemic excursion (LAGE), mean amplitude of glycemic
excursion(MAGE)[6],theM-value[7],meanofdailydiﬀer-
ence (MODD) [8], the J-index [9], high blood glucose index
(HBGI) [10], low blood glucose index (LBGI) [11], average
daily risk range (ADRR) [12], Glycemic Risk Assessment
Diabetes Equation score: GRADE score (hypoglycemia%,
euglycemia%, hyperglycemia%) [13], percentage coeﬃcient
of variation (%CV) [14], hypoglycemic index [14], hyper-
glycemia index [14], index of glycemic control (IGC) [14],
continuous overall glycemic action (CONGA), and 24-hr-
area under the curve (AUC). Each measure is brieﬂy deﬁned
in Table 1 and has been described elsewhere [14]. The M-
value, a glucose swing measure, was computed when the
averagebloodglucosewas5.6mmol/L[7].TheGRADEscore
was based on clinicians’ value judgments of relative impor-
tance of hypo- and hyperglycemia and summarizes diverse
glycemic proﬁles to a single assessment of risk. In reporting
a GRADE score, percentages are used to describe weighted
risks calculated from hypoglycemia%, euglycemia%, and
hyperglycemia% [13]. For example, a GRADE score of 10
(18%, 80%, 2%) indicates an increased glycemic risk with
a risk contribution coming from hypoglycemic episodes.
Conversely, a GRADE score of 10 (2%, 48%, 50%) would
be typical of someone with poorly controlled hyperglycemia.
According to a previous report [13], a GRADE score of <5
reﬂects the euglycemic range.
The AUC for 24hrs was measured by using the
trapezoidal method [15]. The percentages of time (PT)
spent on the blood glucose <3.3mmol/L, >7.8mmol/L,
>8.9mmol/L, and >10mmol/L for 24hrs were computed as
AUCs attributable to these ranges divided by AUC for 24hrs
(Table 1).
2.4. Statistical Analyses. The distribution of each glycemic
indicatorwasevaluatedfornormalityusingtheShapiro-Wilk
test. If values were normally distributed, the mean value was
presented; if not, the median was presented. Study subjects
were divided into two groups: those with FPG levels of
<5.6mmol/L (i.e., NFG group; n = 22) and those with FPG
levels of 5.6–6.9mmol/L (i.e., IFG group; n = 7). Diﬀerences
were evaluated using the chi-square test or Fisher’s exact test
for categorical variables and the t-test or the Wilcoxon rank
sum test for continuous variables according to Shapiro-Wilk
test results. Depending on the distribution of each variable,
Pearson or Spearman correlation coeﬃcient was calculated
for the association between the signiﬁcant CGM indictors
and conventional glycemic indicator (i.e., HbA1c and 1,5-
A G).A llanal y sesw e r ec o nd uct edusingSASso ftwar eV e rsio n
9.12 (Cary, NC, USA). A value of P of <0.05 was considered
to be statistically signiﬁcant.
3. Results
3.1. Subject Baseline Characteristics. Twenty-nine subjects
were 86% male, and had a mean ± SD of age 38 ± 6.9y e a r s ,
body mass index 25±2.3kg/m2,H b A 1 cl ev e l5 .2±0.2%, and
1,5-AG level 25.7 ± 6.5µg/mL. When subjects were divided
into two FPG groups, the proportions of male subjects were
82% versus 100% (P = NS, Fisher’s exact), median insulin
levels were 5.8µU/mL versus 11.5µU/mL (P = 0.021),
HOMA-IR was 1.3 versus 3.5 (P = 0.007), HOMA-beta was
68 versus 60 (P = NS), HbA1c levels were 5.2% versus 5.4%:
P = NS, and 1,5-AG levels were 27µg/mL versus 22µg/mL
(P = 0.001).Thus,subjectswithIFGappearedtohavehigher
levels of insulin and insulin resistance compared with those
with NFG, but retained pancreatic beta-cell function.
3.2. CGM Indicators of Healthy Subjects without Diabetes.
The CGM indicators according to FPG levels are shown in
Table 2. Among CGM measures, including glucose variabil-
ity measures, monitoring excursions, hyperglycemia, hypo-
glycemia,and24-hourAUC,GRADEscoreandeuglycemia%
were statistically diﬀerent (P = 0.022 and P = 0.044, resp.)
between subjects with NFG group and those with IFG group.
GRADE scores were 2.7 (0%, 70%, 30%) in NFG groupISRN Endocrinology 3
Table 1: CGM indicators.
Glycemic measure Brief deﬁnition Reference
MBG Mean of all glucose values 5.7mmol/L [20], 5.8mmol/L [26]f o r
healthy individuals
SD SD of all glucose values 1mmol/L [20], 0.8mmol/L [26]f o r
healthy individuals
LAGE Blood glucose (BG)max-BGmin
1.4–5.7mmol/L for healthy individuals
[16]
MAGE Average amplitude of upstrokes or downstrokes with magnitude
greater than 1 SD
1.2–3.3mmol/L for healthy individuals
[6]
M-value Weighted average of glucose values, with progressively larger penalties
for more extreme values
0 for healthy individuals, 0–18 for good
control [7]
MODD Mean diﬀerence between glucose values obtained at the same time of
day on two consecutive days
0.3–0.5mmol/L for healthy individuals,
0.6–2.0mmol/L for stable diabetes [8]
J-index 0.001 × (mean + SD)2 10 <J<20 as Ideal glucose control [9]
HBGI High blood glucose index <4.5 for low risk of hyperglycemia [10]
LBGI Low blood glucose index ≤1.1 for minimal risk [11]
ADRR Range to predict both hypoglycemia and hyperglycemia <10 for low risk [12]
GRADE score
Weighted average of glucose values, giving a greater penalties to
hypoglycemia than hyperglycemia, and to more severe departures
from the target level of 5.8mmol/L
<5 reﬂects the euglycemic range [13]
hypoglycaemia Percentage of GRADE score attributable to glucose values below
3.9mmol/L [13]
euglycaemia Percentage of GRADE score attributable to glucose values within the
range 3.9–7.8mmol/L [13]
hyperglycaemia Percentage of GRADE score attributable to glucose values above
7.8mmol/L [13]
%CV 100 ×SD/Mean 14 with range 13–16 for healthy
individuals [27]
IGC Sum of hyperglycemia index and hypoglycemia index [14]
CONGA24 Measure of within-day glucose variability; SD of diﬀerences between
any glucose value and another one exactly 24 hours latter [14]
24hrs-AUC AUC attributable to glucose values above 2.2mmol/L 135mmol·24h/L for healthy individuals
[20]
PT > 7.8mmol/L AUC attributable to glucose values above 7.8mmol/L/24hr-AUC 4% for healthy individuals [20, 26]
PT > 8.9mmol/L AUC attributable to glucose values above 8.9mmol/L/24hr-AUC N/A
PT > 10mmol/L AUC attributable to glucose values above 10mmol/L/24hr-AUC 0.2 ±0.5 for healthy individuals [20]
PT < 3.3mmol/L AUC attributable to glucose values within the range
2.2–3.3mmol/L/24hr-AUC 1 ±1 for healthy individuals [20]
Full name of each abbreviation is given in text.
versus 3.9 (10%, 40%, 50%) in IFG group. Even though both
groupshadeuglycemiareferringtoapreviousliterature[13],
GRADE score was signiﬁcantly higher in IFG group than
in NFG group and euglycemia% was signiﬁcantly higher in
NFG group than in IFG group.
Except for GRADE score, the remaining CGM indicators
did not diﬀer signiﬁcantly between the two groups. Means
or medians of these CGM measures fell in the normal
ranges for healthy individuals or individuals with stable
diabetes [6–8, 12–14, 16, 17]. The median percentage time
within a 24-hour period that the blood glucose level was
>7.8mmol/L was greater than 10% in both NFG and IFG
groups. This means that approximately 10% of CGM for
24hrs in both two groups reached the glucose tolerance
threshold of 7.8mmol/L at some time during the 24-hour
monitoring period.
The median percentages of time within a 24-hour
period in NFG group that the blood glucose levels were
>7.8mmol/L,>8.9mmol/L,and>10mmol/Lwere13%(3%,
23%), 1% (0%, 6%), and 0% (0%, 1%), respectively. When
calculated on a head-count basis in the same group (i.e.,
NFG group), AUC above 7.8mmol/L was observed in 19/22
subjects, and AUC above 8.9mmol/L in 12/22 subjects, and
AUC above 10mmol/L in 7/22 subjects at some point within
24hrs.
3.3.CorrelationCoeﬃcientsbetweenGRADEScoreandHbA1c
and 1,5-AG. Table 3 shows the correlation coeﬃcients
between GRADE score (hyopglycemia%, euglycemia% hy-
perglycemia%), and HbA1c and 1,5-AG in the entire subject.
GRADE score and euglycemia% were highly correlated with
1,5-AG (r =− 0.583 and P = 0.001, and r = 0.512 and4 ISRN Endocrinology
Table 2: CGM indicators of healthy subjects without diabetes.






(n = 7) P-value
MBG (mmol/dL) 6.4 ±0.86 .4 ±0.76 .6 ±1.1 0.471
SD (mmol/dL) 1.2 ±0.41 .2 ±0.41 .3 ±0.4 0.562
LAGE (mmol/dL) 4.5 ±1.64 .4 ±1.64 .9 ±1.8 0.414
MAGE (mmol/dL) 2.3 ±0.82 .2 ±0.82 .5 ±0.7 0.388
M-value 7.3 ±3.26 .8 ±3.18 .8 ±3.1 0.153
MODD (mmol/dL) 1.3 ±0.51 .3 ±0.51 .4 ±0.5 0.593
J-index 19 ±4.51 8 ±3.92 1 ±6.1 0.304
HBGI 0.5 (0.3, 1.0) 0.5 (0.3, 0.9) 1.0 (0.3, 1.2) 0.102
LBGI 0.4 (0.2, 1.4) 0.4 (0.2, 0.8) 0.9 (0.2, 2.0) 0.228
ADRR 4.6 (2.6, 7.3) 4.6 (2.6, 7.1) 7.7 (4.1, 11.3) 0.142
GRADE score 3.0 ±1.32 .7 ±1.13 .9 ±1.4 0.022
hypoglycaemia 0.0 (0.0, 0.1) 0.0 (0.0, 0.1) 0.0 (0.0, 0.2) 0.446
euglycaemia 0.6 ±0.20 .7 ±0.20 .5 ±0.2 0.044
hyperglycaemia 0.3 ±0.20 .3 ±0.20 .4 ±0.2 0.130
CV % 19.6 (11.9, 23.8) 18.2 (11.9, 23.7) 20.7 (11.4, 24.8) 0.371
IGC 1.6 (0.7, 3.6) 1.7 (0.7, 3.6) 0.8 (0.4, 8.2) 0.460
CONGA24 1.1 ±0.41 .1 ±0.41 .1 ±0.3 0.659
24hrs-AUC (mmol ·24h/dL) 155 ±19 155 ±19 160 ±19 0.427
Percentage of time at glycemia (%)
>7.8mmol/L 16% (5%, 27%) 13% (3%, 23%) 19% (7%, 30%) 0.212
>8.9mmol/L 1% (0%, 5%) 1% (0%, 6%) 3% (1%, 5%) 0.238
>10mmol/L 0% (0%, 1%) 0% (0%, 1%) 0% (0%, 0%) 0.314
< 3.3mmol/L 0% (0%, 0%) 0% (0%, 0%) 0% (0%, 2%) 0.134
Presented by mean ± SD or median (25%, 75%) depending on the normality based on Shapiro-Wilk test.
P value was based on either t-test or Wilcoxon sum rank test depending on the normality based on Shapiro-Wilk test.
P = 0.005, resp.) and moderately correlated with HbA1c
(r = 0.450 and P = 0.014, and r =− 0.191 and P = 0.321,
resp.).
4. Discussion
This study demonstrated that GRADE score and euglyce-
mia% signiﬁcantly diﬀered between subjects with NFG and
those with IFG, although GRADE score was less than 5 in
both groups, suggesting glucose proﬁles in both groups were
euglycemia. Furthermore, GRADE score and euglycemia%
were highly correlated with 1,5-AG in this study. Previous
literatures suggest that 1,5-AG is an indicator of glycemic
variability [18, 19]. Previously Yamanouchi et al. [18]
reported that 1,5-AG levels manifested greater ﬂuctuation
of plasma glucose even though the mean plasma glucose
and HbA1c levels suggested good control. Furthermore,
Kishimoto et al. [19] suggest that the plasma 1,5-AG concen-
tration can be a useful index of the daily excursion of blood
glucose, especially in patients with well-controlled diabetes.
In our study, CGM indicators such as MAGE, M-value, and
LARGE that reﬂect glucose excursion or ﬂuctuation were not
signiﬁcantlydiﬀerentbetweenthetwoFPGgroups.However,
we found that there was signiﬁcant correlation between
GRADE score and 1,5-AG. This may suggest that a GRADE
score may be a sensitive CGM indicator to discriminate
glucose proﬁles in subjects with NFG from those in subjects
with IFG.
ExceptforGRADEscore,theremainingCGMindicators,
including glucose variability measures, monitoring excur-
sions, hyperglycemia, hypoglycemia, and 24-hour AUC, did
not diﬀer signiﬁcantly between subjects with NFG and
those with IFG. In fact, means or medians of these CGM
measures in both groups fell in the normal ranges for healthy
individuals and individuals with stable diabetes [6–11, 13,
14, 16, 20–22] suggesting that glucose proﬁle in healthy
individuals without diabetes was less variable than those for
diabetics.
AlthoughglucosevariabilitydetectedbyCGMwasfound
to be small, we found that more than 10% of the 24-
hour AUC was above 7.8mmol/L and 1% of the 24-hour
AUC above 8.9mmol/L, even in subjects with FPG levels
of <5.6mmol/L. Indeed, the plasma glucose level, at some
point within a 24-hour period, exceeded the IGT threshold
of 7.8mmol/L in nearly all individuals who belonged to NFG
group, exceeded 8.9mmol/L in half of subjects, and exceeded
10mmol/L in one-third of subjects. A 2010 ADA reportsISRN Endocrinology 5
Table 3: Correlation coeﬃcients between GRADE score (hyopglycemia%, euglycemia%, hyperglycemia%), and HbA1c and 1,5-AG in the
entire subject.
GRADE score Hypoglycemia% Euglycemia% Hyperglycemia%
Coeﬃcient P Coeﬃcient P Coeﬃcient P Coeﬃcient P
HbA1c 0.450 0.014 −0.264 0.167 −0.191 0.321 0.396 0.034
1,5-AG −0.583 0.001 −0.191 0.331 0.512 0.005 −0.411 0.030
thathealthyindividuals with FPGlevels of <5.6mmol/L have
no risk of future cardiovascular disease complications in
diabetes and do not require any intervention [23]. However,
it requires a justiﬁcation.
For example, a large clinical trial revealed that, even in
individuals with FPG and 2-hour plasma glucose (2hPG)
levels within the normoglycemic range, higher 2hPG was
associated with insulin resistance and increased cardiovas-
cular disease mortality [24]. In view of the evidence that
the glycemic proﬁle in healthy individuals is related to
the pathogenesis of cardiovascular complications associated
with abnormal glucose metabolism, the accuracy of the
current diagnostic practice such as self-monitoring of blood
glucose must be improved in order to capture abnormal
glycemic proﬁles. In this regard, CGM in healthy individuals
may not be acceptable for screening a larger population
for risk of future diabetes due to the costs involved and
resources needed. However, we found that 1,5-AG level was
signiﬁcantly correlated with GRADE score that was the only
signiﬁcant CGM indicator. Thus, it is suggested that 1,5-AG
may be a useful alternative for CGM to discriminate glucose
proﬁles between healthy individuals with NFG and those
with IFG. Future studies with a larger sample size will be
required to verify the results of the present study.
In addition to small number of study subjects, our study
has several limitations. First, since a 75-gram oral glucose
tolerance test (OGTT) was not performed, we might have
had diabetes at inclusion. According to a previous report,
because FPG alone fails to diagnose 30% of diabetes who
werediagnosedbya2-hourplasmaglucose[25].Inaddition,
IGT can be easily missed as oriental population are often
characterized by postprandial hyperglycaemia. Second, FPG
levels in this study were assessed only once at baseline.
The inter- and intracoeﬃcients of variations in glucose
values may have caused some random misclassiﬁcation of
subjects into the two FPG categories and thereby inﬂu-
enced our results. Third, although the measurement was
performed under real-life conditions, lifestyle-related factors
thatinﬂuenceglucoselevels,suchasexercise,sleep,andstress
including emotional and physical stress, were not examined.
Fourth, 85% of our study subjects were male, which might
aﬀect the results. Finally, this study assessed patient at risk of
diabetes by using FPG and HbA1c alone. Thus, the results of
our study should be interpreted with caution.
5. Conclusion
Despite these limitations, even under real-life conditions,
the glucose proﬁles of healthy individuals, including subjects
with NFG and IFG, are far less variable than those of diabetic
individuals [6–11, 13, 14, 16, 20, 21]. Nevertheless, nearly
all individuals with FPG levels of <5.6mmol/L exceeded the
impaired glucose tolerance threshold of 7.8mmol/L at some
point within a 24-hour period, indicating that glucose levels
in healthy individuals frequently reach the impaired glucose
tolerance threshold. Although most CGM measures did not
diﬀer signiﬁcantly between the two FPG groups, the GRADE
score may be a sensitive indicator that distinguishes the
glucose proﬁles of subjects with NFG from those of subjects
with IFG.
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